Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalysed by human liver microsomes
Bourrie M., Meunier V., Berger Y., Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalysed by human liver microsomes. J. Pharmacol. Exp. Ther. 277:1996;321-332.
Biotransformation of parathion in human liver:participation of CYP3A4 and its inactivation during microsomal parathion oxidation
Butler A.M., Murray M. Biotransformation of parathion in human liver:participation of CYP3A4 and its inactivation during microsomal parathion oxidation. J. Pharmacol. Exp. Ther. 280:1997;966-973.
Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes
Eagling V.A., Tjia J.F., Back D.J. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br. J. Clin. Pharmacol. 45:1998;107-114.
Automated discrete kinetic method for erythrocyte acetylcholinesterase and plasma cholinesterase
Lewis P.J., Lowing R., Gompertz D. Automated discrete kinetic method for erythrocyte acetylcholinesterase and plasma cholinesterase. Clin. Chem. 27:1981;926-929.
The role of metabolism in determining susceptibility to parathion toxicity in man
Mutch E., Blain P.G., Williams F.M. The role of metabolism in determining susceptibility to parathion toxicity in man. Toxicol. Lett. 107:1999;177-187.